Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Charleroi – page 9

201 clinical trials in Charleroi, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Charleroi at a glance
201
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

201 trials in Charleroi

Open in trial search

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Transitional cell carcinoma

Not yet recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Gastric cancer+1

Not recruiting

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Vitiligo

Not recruiting

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Hormone-refractory prostate cancer+1

Not recruiting

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Not recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Charleroi

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, particularly in breast cancer, lung cancer, and head and neck cancers. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • HER2-positive breast cancer imaging studies
  • Non-small cell lung cancer therapies
  • Triple-negative breast cancer treatment

Multiple trials investigating personalized medicine approaches and biomarker-driven treatments.

02 Cardiovascular Studies

Research examining treatments for coronary artery disease and post-cardiac arrest care. Trials focus on innovative stent technologies and antiplatelet therapy optimization.

  • Antiplatelet therapy optimization
  • Post-cardiac arrest management
  • Novel stent technologies

Emphasis on improving patient outcomes through targeted interventional approaches.

03 Dermatology and Immunology

Clinical investigations targeting inflammatory skin conditions and immune-mediated disorders. Studies evaluate novel treatments for psoriasis and other dermatological conditions.

  • Plaque psoriasis treatments
  • Prurigo nodularis therapies
  • Severe asthma management

Focus on developing targeted therapies for chronic inflammatory conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.